SSY Group (02005.HK) Secures Production Approval for Four Drugs; Second Domestic Firm to Launch Emedastine Difumarate Eye Drops

NewTimeSpace News: SSY Group Limited (02005.HK) issued a voluntary announcement on May 21, 2026, releasing the latest updates on its pharmaceutical product pipeline.
As for 0.05% Emedastine Difumarate Eye Drops (0.35ml:0.175mg), the Group is the second domestic company granted NMPA production registration approval. Classified as Class 4 chemical drug, it is deemed consistency evaluation compliant, indicated for temporary relief of signs and symptoms of allergic conjunctivitis.
In terms of 5mg Perindopril Arginine Tablets, the Group ranks the third in China to obtain relevant approval. Belonging to Class 4 chemical drugs, it is exempted from further consistency evaluation, mainly used for the treatment of hypertension and congestive heart failure.
Peramivir Sodium Chloride Injection has obtained production approval as a Class 4 chemical drug with consistency evaluation passed, for the treatment of influenza A and influenza B.
Bumetanide Injection (1ml:0.5g) is approved as a Class 3 chemical drug and deemed qualified for consistency evaluation. It is applied in the treatment of edematous diseases and hypertension, as well as the prevention of acute renal failure. Previously, the Group’s bumetanide API has been officially registered and approved by the NMPA for matching marketed finished medicines.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.